Saverna Therapeutics was founded 2017 with a mission to change the way pharmaceutical companies discover and develop safe, orally active small molecules that target non-coding RNA-biology to treat diseases with unmet medical need.
Saverna Therapeutics aims to discover highly active, selective and cell-permeable low molecular weight molecules that target RNA biology.
Saverna Therapeutics to date has been financed through a mixture of self-funding, grant awards from Switzerland and Europe via Innosuisse and Eurostars programs.